NCATS develops novel approaches to improve the process of joining basic science discoveries with initial testing of therapies in humans.
-
Research
-
Preclinical Innovation
Responding to the COVID-19 Pandemic
NCATS is supporting research activities to address the novel coronavirus 2019 (SARS-CoV-2) and the disease it causes (COVID-19). Learn about the projects that are cutting through operational roadblocks to contribute to new knowledge about COVID-19.
PaVe-GT: Paving the Way for Rare Disease Gene Therapies
The NCATS-led Platform Vector Gene Therapy (PaVe-GT) pilot project seeks to increase the efficiency of clinical trial startup by using the same gene delivery system and manufacturing methods for multiple rare disease gene therapies.
Collaborating to Overcome Roadblocks to Advance Melanoma Therapy
NCATS scientists used high-throughput screening to help colleagues at NCI identify existing compounds and drugs that could lead to improvements in a therapy for a form of metastatic melanoma, a potentially deadly skin cancer.
Improving the Drug Development ProcessCreating and testing innovative methods to improve and accelerate the drug development process and find new treatments for patients faster.
Repurposing DrugsDiscovering new uses for approved drugs to provide the quickest possible transition from bench to bedside.
Testing & Predictive ModelsDeveloping better model systems for drug and toxicity testing.
Core TechnologiesUsing state-of-the-art resources to enable the ongoing operation of all NCATS translational research activities.
Improving the Drug Development Process
Creating and testing innovative methods to improve and accelerate the drug development process and find new treatments for patients faster.
Discovering new uses for approved drugs to provide the quickest possible transition from bench to bedside.
Developing better model systems for drug and toxicity testing.
Using state-of-the-art resources to enable the ongoing operation of all NCATS translational research activities.
Work with Us
NCATS preclinical programs and resources focus on key obstacles and inefficiencies in the translational process, overcoming bottlenecks that slow the development of new treatments for patients.
Learn more about how to access NCATS programs and expertise.
Inside the NCATS Laboratories
Take a video tour of our labs and see firsthand how our researchers work to get more treatments to more patients more quickly.
Learn more about NCATS’ Achievements in Advancing Translational Sciences.
NCATS Programs & Resources Supporting Preclinical Innovation
- 3-D Tissue Bioprinting Program
- Biomedical Data Translator
- Bridging Interventional Development Gaps (BrIDGs)
- Chemistry Technology
- Discovering New Therapeutic Uses for Existing Molecules (New Therapeutic Uses)
- Extracellular RNA Communication
- Matrix Combination Screening
- NCATS Chemical Genomics Center (NCGC)
- NCATS Pharmaceutical Collection
- Pfizer's Centers for Therapeutic Innovation (CTI) for NIH Researchers
- RNA Interference (RNAi)
- Therapeutics for Rare and Neglected Diseases (TRND)
- Tissue Chip for Drug Screening
- Toxicology in the 21st Century (Tox21)
-
